Advantages of Oncolytic Viruses as Immunotherapies to be Discussed by Catalent Gene Therapy Expert at World Vaccine Congress – PR Web

SOMERSET, N.J. (PRWEB) September 22, 2020

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that George Buchman, Ph.D., Vice President, Preclinical & Process Development, Catalent Cell & Gene Therapy, will present at the World Vaccine Congress, which will take place virtually on Sept. 28 October 1, 2020.

On Sept. 30 at 4:05 p.m. EST, Dr. Buchman will present Next-Generation Vaccines and Oncolytic Viruses: Current Challenges and Future Promise, giving an overview of the benefits and limitations of oncolytic viruses as immunotherapies. His presentation will discuss the manufacturing and analytical considerations, as well as a collaborative study that evaluates a new technology to assess transfection efficiency.

Dr. Buchman joined Catalent through its acquisition of Paragon Gene Therapy in 2019. He has more than 30 years of experience in the biotech industry, and has held roles at companies including Life Technologies (now Thermo Fisher), Celera Genomics and Gene Logic. Dr. Buchman obtained a bachelors degree in biochemistry from Albright College, Reading, Pennsylvania, and a doctorate in biochemistry from University of Maryland.

For more information, please visit https://biologics.catalent.com/events/world-vaccine-congress/.

About Catalent Cell & Gene TherapyWith deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. When it acquired MaSTherCell, Catalent added expertise in autologous and allogeneic cell therapy development and manufacturing to position it as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. An experienced partner, Catalent Cell & Gene Therapy has worked with industry leaders across 70+ clinical and commercial programs. For more information, visit biologics.catalent.com/cell-gene-therapy/

About CatalentCatalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.

Share article on social media or email:

See the original post here:
Advantages of Oncolytic Viruses as Immunotherapies to be Discussed by Catalent Gene Therapy Expert at World Vaccine Congress - PR Web